Innovar Treatment for Meniere's Disease

Abstract

Patients with intractable vertigo due to clinical Meniere's disease were offered treatment with Innovar, a neurolept analgesic. The patients were from a single clinical practice, had failed conventional dietary and medical treatment and were eligible on clinical grounds for endolymphatic sac surgery. After a follow-up of 2-8 years, 58% of patients had long-lasting relief of vertigo. Hearing was not affected. Risk factors for a favorable response were male gender, fluctuating hearing, and early stage of the disorder. Innovar is a safe, cost-effective second-line therapy for patients with Meniere's disease who have failed conventional first-line medical therapy.

Intermittent Pressure Therapy of Intractable Ménière's Disease Using the Meniett Device: A Preliminary Report

“… 8,9 Intravenous Innovar has had limited success in the early, fluctuant stage of the disorder. 10 Vestibular suppressants are helpful for symptom suppression. Vasodilators, herbs, acupuncture, and antiallergy therapy have all been used as nonspecific measures.…”